<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04005053</url>
  </required_header>
  <id_info>
    <org_study_id>PSYCH-2018-26890</org_study_id>
    <nct_id>NCT04005053</nct_id>
  </id_info>
  <brief_title>Signatures of N-Ac for Non-Suicidal Self-Injury in Adolescents</brief_title>
  <official_title>Identifying Biological Signatures of N-Acetylcysteine for Non-Suicidal Self-Injury in Adolescents and Young Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To measure NAC-induced changes to concentrations of glutathione (GSH) in the anterior&#xD;
      cingulate cortex (ACC) as measured by magnetic resonance spectroscopy (MRS) in 36 adolescents&#xD;
      and young adults with NSSI (12 in each group: high, low, and placebo).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a double-blind, placebo controlled, 4-week course of two-tiered&#xD;
      N-acetylcysteine (NAC) dosing focused on identifying the optimal dose to achieve meaningful&#xD;
      change in measurable biomarkers (glutathione and glutamate).&#xD;
&#xD;
      This design will allow us to confirm acute biological changes, select the optimal dose for&#xD;
      achieving biological effects, and examine dose/concentration-response relationships with&#xD;
      respect to biological markers and pharmacokinetics.&#xD;
&#xD;
      Brief schedule of activities: Subjects will be recruited through community and clinical&#xD;
      settings and screened over the phone. There will be a total of 4 in-person visits and two&#xD;
      sets of on-line study activities.&#xD;
&#xD;
      Eligible participants will be assigned to one of 3 groups (double-blinded): a low-dose NAC&#xD;
      group (3600 mg/day), a high-dose NAC group (5400mg/day), and placebo (PBO). The study&#xD;
      intervention period is 4 weeks. Total participation is up to 8 weeks, depending on the length&#xD;
      of time between Day 0 and Day 1.&#xD;
&#xD;
      The investigators will recruit 36 adolescents and young adults aged 16-24 years. There will&#xD;
      be 12 participants in each group (PBO, 3600mg/day, 5400mg/day). The investigators will use a&#xD;
      minimization procedure to ensure that the participants in these 3 groups will have similar&#xD;
      age, clinical severity and medication status.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in glutathione concentrations in ACC</measure>
    <time_frame>28 days</time_frame>
    <description>Number of participants who achieve a 5% increase in glutathione (GSH) concentrations in the anterior cingulate cortex (ACC) as measured by magnetic resonance spectroscopy (MRS) compared to placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in GSH reduced-to-oxidized ratio</measure>
    <time_frame>28 days</time_frame>
    <description>Number of participants who achieve an increase of at least 50% in the reduced-to-oxidized ratio of glutathione (GSH) in the blood compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glutamate concentrations</measure>
    <time_frame>28 days</time_frame>
    <description>Number of participants who achieve at least a 5% decrease in the concentrations of glutamate (GLU) in the anterior cingulate cortex (ACC) compared to placebo</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Self-Harm</condition>
  <condition>Depression</condition>
  <condition>Suicide</condition>
  <arm_group>
    <arm_group_label>Low-Dose NAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3600 NAC mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-Dose NAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5400 NAC mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetyl cysteine</intervention_name>
    <description>3600 or 5400 mg/day N-acetyl cysteine</description>
    <arm_group_label>High-Dose NAC</arm_group_label>
    <arm_group_label>Low-Dose NAC</arm_group_label>
    <other_name>N-acetylcysteine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Current frequency of at least one NSSI episode in the past 2 months&#xD;
&#xD;
          -  â‰¥ 5 past episodes of NSSI with significant tissue damage (e.g. scars present)&#xD;
&#xD;
          -  Psychotropic medications are dose-stable for 1 month&#xD;
&#xD;
          -  Ability to understand study procedures and to comply with them for the entire length&#xD;
             of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any MRI contraindications (e.g. metal plates, claustrophobia, braces, implanted&#xD;
             devices)&#xD;
&#xD;
          -  Any current serious medical illness as defined by medical history&#xD;
&#xD;
          -  Current Substance Use Disorder (except Tobacco Use Disorder)&#xD;
&#xD;
          -  Primary psychotic disorder (e.g. schizophrenia, schizoaffective disorder,&#xD;
             schizophreniform disorder)&#xD;
&#xD;
          -  Neurodevelopmental disorder such as mental retardation or autism&#xD;
&#xD;
          -  Changes in psychotropic medications in past 1 month&#xD;
&#xD;
          -  Taken NAC or glutathione on a regular basis in the past 6 months&#xD;
&#xD;
          -  Currently pregnant, planning to become pregnant, currently breastfeeding, or&#xD;
             unwillingness to use contraception throughout the study.&#xD;
&#xD;
          -  Allergy/sensitivity to N-acetylcysteine.&#xD;
&#xD;
          -  Inability or unwillingness of individual or legal guardian/representative to give&#xD;
             written informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>24 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alanna Nascene</last_name>
    <phone>612-434-0852</phone>
    <email>anascene@umn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Cullen, MD</last_name>
      <phone>612-273-9732</phone>
      <email>rega0026@umn.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>June 27, 2019</study_first_submitted>
  <study_first_submitted_qc>June 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2019</study_first_posted>
  <last_update_submitted>December 15, 2020</last_update_submitted>
  <last_update_submitted_qc>December 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Suicide</mesh_term>
    <mesh_term>Self-Injurious Behavior</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

